S100A8/A9 as a target in metabolic diseases to inhibit the acceleration of cardiovascular disease [ 2016 - ]

Research Grant

Researchers: A/Pr Andrew Murphy (Principal investigator) ,  Prof Merlin Thomas

Brief description Obesity and diabetes are the leading cause of premature death, due to accelerated cardiovascular disease (CVD). The abundance of blood monocytes influences the progression and regression of CVD. We discovered that S100A8/A9 promotes monocyte production in obesity and diabetes. This project will explore how S100A8/A9 is produced in diabetes and obesity and if blocking its function using a novel drug will prevent obesity and diabetes associated CVD.

Funding Amount $554,990.00

Funding Scheme Project Grants

Notes Standard Project Grant